Eben Tessari
Founder bei KINIKSA PHARMACEUTICALS, LTD.
Vermögen: 2 Mio $ am 31.03.2024
Aktive Positionen von Eben Tessari
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Chief Operating Officer | 03.01.2022 | - |
| Founder | 01.07.2015 | - | |
| Corporate Officer/Principal | 01.07.2015 | 03.01.2022 |
Karriereverlauf von Eben Tessari
Ehemalige bekannte Positionen von Eben Tessari
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01.12.2014 | 01.07.2015 |
Civitas Therapeutics, Inc.
 Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Corporate Officer/Principal | 01.11.2013 | 01.12.2014 |
Ausbildung von Eben Tessari
| Boston University | Graduate Degree |
| Suffolk University | Graduate Degree |
| Northeastern University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
| Israel | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| Graduate Degree | 2 |
| Chief Operating Officer | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Börse
- Insiders
- Eben Tessari
- Erfahrung
